Meeting
2018 ASCO Annual Meeting
Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
Authors
Lynn G. Feun
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
Lynn G. Feun , Ying-Ying Li , Medhi Wangpaichitr , Patricia Denise Jones , Stephen P. Richman , Beatrice Madrazo , Deukwoo Kwon , Paul Martin , Peter Joel Hosein , Niramol Savaraj
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02658019
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4086)
DOI
10.1200/JCO.2018.36.15_suppl.4086
Abstract #
4086
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
First Author: Oxana V. Crysler
Poster
2022 ASCO Annual Meeting
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel
Poster
2019 ASCO Annual Meeting
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
First Author: Thomas Yau
Poster
2018 Gastrointestinal Cancers Symposium
Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.
First Author: Sunyoung S. Lee